Complexities of Relapsed/Refractory AML: Aligning Strategies to Maximize Outcomes
Please complete Pre-test
Chapter 1 of 1
Release Date: September 13, 2021
Expiration Date: September 13, 2022
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Join Dr. Short as he explores challenges in managing relapsed/refractory AML. Topics include analysis of the role of cytogenetic and molecular aberrations in prognosis and relapse risk, standard and targeted therapies, and new data on emerging therapies for relapsed/refractory AML.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Describe the current paradigm for AML diagnosis and treatment, including the use of cytogenetic and molecular aberrations related to determination of probability for relapse
- Align and individualize current standards of care and therapeutic strategies to optimize outcomes in relapsed/refractory AML
- Outline efficacy and safety data emerging from the most recent clinical trials evaluating therapeutic agents in the relapsed setting in AML
Complexities of Relapsed/Refractory AML: Aligning Strategies to Maximize Outcomes – Nicholas J. Short, MD
Instructions for Participation and Credit
This activity is eligible for credit through September 13, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Nicholas J. Short, MD
Department of Leukemia,
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center
Dr. Nicholas Short received his medical degree from Baylor College of Medicine, Houston, Texas. He completed a clinical residency in internal medicine at Brigham and Women's Hospital, Boston, Massachusetts, and a clinical fellowship in hematology-oncology at The University of Texas MD Anderson Cancer Center, Houston. Dr. Short is an Assistant Professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.
Dr. Short received American Board of Internal Medicine certification in internal medicine, hematology, and medical oncology. He is a member of the American Society of Clinical Oncology, American Society of Hematology, Society of Hematologic Oncology, and the European Hematology Association. In addition, he is on the editorial review board of Cancer Treatment and Research Communications (CTARC), Journal of Hematology & Oncology, Annals of Blood, Frontiers in Oncology, and Expert Opinion on Pharmacotherapy, and is a journal reviewer for dozens of peer-reviewed journals
As a clinical and translational investigator, Dr. Short’s interests include acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL), as well as novel methods to detect minimal/measurable residual disease (MRD) for acute leukemias. He serves as principal investigator or co-principal investigator on many Phase I and II clinical trials and has authored more than 100 peer-reviewed manuscripts and numerous abstracts that have been presented at national and international conferences.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.
©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-035-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.|
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Nicholas Short has relevant financial relationships from Amgen Inc. and Novartis AG, as well as relevant financial relationships related to consulting from AstraZeneca, Jazz Pharmaceuticals plc, and NGM Biopharmaceuticals. He has received research grant(s) from Astellas Pharma US, Inc. and Takeda Oncology.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer Reviewer Disclosure
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.